Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial

AD symptom improvement was maintained up to Week 200 with baricitinib 4 mg. After down-titration, the vIGA-AD (0,1) response patient subgroup maintained clear or almost clear skin and itch response improvement. Clear or almost clear skin achievement may help identify optimal candidates for down-titration after 52 weeks of full-dose treatment.